Kenji Ohmori (Institute for Molecular Science, National Institutes of Natural Sciences, Japan) has collaborated with Matthias Weidemüller (University of Heidelberg), Guido Pupillo (University of Strasbourg), Claudiu Genes (University of Innsbruck) and their coworkers to develop the world’s fastest simulator that can simulate quantum mechanical dynamics of a large number of particles interacting with each other within one billionths of a second.
A team of researchers from the University of Manchester announced Monday they had taken a significant step forward in the creation of viable quantum computers. In a study published in the latest edition of the journal Chem, the researchers provided evidence that large molecules made of nickel and chromium could be used as qubits — the quantum computing equivalent of the bits used to store and process information in conventional computers.
According to the study, it is possible, at least in theory, to use molecular chemistry to connect these molecules, thereby creating several stable qubits that can then be used to create two-qubit logic gates.
“We have shown that the chemistry is achievable for bringing together two-qubit gates — the molecules can be made and the gates can be assembled,” lead author Richard Winpenny said in a statement. “The next step is to show that they work.”
A lot has happened since we first heard about the AirMule, a prototype VTOL (Vertical Takeoff and Landing) aircraft that features internal rotor blades – these work along with the horizontal-thrust ducted fans visible at the rear. First, it made some tethered autonomous test flights. Then, it flew untethered for a short distance. Now, known as the Cormorant UAV, it’s made its first full untethered autonomous flight … although there were a couple of hiccups.
Designed by Israeli firm Tactical Robotics, the Cormorant is designed to deliver troops, civilian passengers or other cargo within tight quarters where helicopters with exposed rotor blades just can’t go. With the UAV in its name standing for Unmanned Aerial Vehicle, the idea is that it will perform these tasks either autonomously or by remote control.
The latest test took place in Israel on Nov. 3rd, lasting only about two minutes and involving low flight over uneven terrain. While the aircraft did successfully demonstrate autonomous flight modes such as takeoff, climb, acceleration, cruise, deceleration, descent, turns, hover and touchdown, it is hoped that subsequent flights will be able to smooth out the transitions between those modes.
“Hopefully, if we’re successful in the private-sector community, NASA’s going to save a boatload of money, on multiple locations [in orbit] — not just one — with more volume than they’ve ever had before,” Bigelow founder and CEO Robert Bigelow said here Wednesday (Oct. 12) at the 2016 International Symposium for Personal and Commercial Spaceflight (ISPCS). “So, whether it’s Axiom or us or other people, that is the future.”
A team of scientists in China has become the first to treat a human patient with the groundbreaking CRISPR-Cas9 gene-editing technique. While the results of the trial are uncertain, it’s a historic milestone that should serve as a serious wakeup call to the rest of the world.
(Phys.org)—A team of researchers working at West China Hospital in Chengdu has for the first time injected CRISPR–Cas9 edited cells into a human test subject. Nature reports that the procedure occurred on October 28, and that thus far, the patient is doing “fine.”
Modified cells have been injected into human subjects before, of course, but using different techniques. CRISPR-Cas 9 is considered to be a more efficient approach. In this new effort, the researchers isolated immune cells retrieved from a blood sample, then used CRISPR-Cas9 to locate and disable the PD-1 protein in them, which prior research has shown slows an immune response by a cell. The idea is that disabling the protein will allow the immune system to put up more of a fight against tumor growth. The edited cells were placed in a container where they were fed and allowed to multiply—the entire collection was then gathered and injected into a patient suffering from a type of lung cancer that had not responded to any other treatment type.
The CRISPR technique involves using an RNA guide that binds to a particular DNA sequence and an enzyme (the Cas9 part) that can cut strands of DNA at preselected spots, allowing for removing strands or adding new ones.